FOXO4-DRI

FOXO4-DRI is derived from the p53-binding region of the FOXO4 transcription factor. The peptide uses a D-retro-inverso configuration, meaning the amino-acid sequence is reversed and composed of D-amino acids to improve resistance to enzymatic degradation.

FOXO4-DRI disrupts the interaction between FOXO4 and p53 inside senescent cells. Normally, FOXO4 binds to p53 and prevents it from initiating apoptosis. When this interaction is blocked, p53 activates cellular pathways that lead to programmed cell death. This mechanism allows the peptide to selectively target senescent cells in experimental systems.

FOXO4-DRI is studied as a senolytic peptide, meaning it selectively eliminates senescent cells. Experimental studies suggest that removal of these cells may improve tissue maintenance and reduce inflammatory signaling associated with cellular aging. Researchers are exploring its potential role in aging biology and regenerative medicine.

Human safety data are limited because FOXO4-DRI remains an investigational compound. Experimental studies report generally good tolerance under controlled conditions. Potential concerns include inflammatory responses following senescent-cell clearance and unknown long-term safety.

FOXO4-DRI is produced using Fmoc solid-phase peptide synthesis, assembling amino acids sequentially on a resin support. After cleavage, the peptide is purified by high-performance liquid chromatography and verified by mass spectrometry to confirm identity and purity.

FOXO4-DRI is classified as an investigational peptide. It has not been approved by the U.S. FDA, EMA, or other major regulatory authorities for therapeutic use. The compound remains in the experimental stage and is studied primarily in scientific research.

There are no standardized dosing guidelines for FOXO4-DRI in humans. Experimental dosing varies depending on study design and research models. Any administration should occur only within approved research protocols.

• Do follow approved research protocols and laboratory safety procedures.
• Do verify peptide purity and identity before experimental use.
  ​
• Don’t combine with other senolytic compounds without experimental justification.
• Don’t use outside controlled research settings.

• Q: What does “DRI” mean?
• A: It stands for D-retro-inverso, a structural modification that increases peptide stability.
  ​
• Q: What are senescent cells?
• A: Senescent cells are aged or damaged cells that stop dividing but continue releasing inflammatory signaling molecules.
  ​
• Q: What type of peptide is FOXO4-DRI?
• A: It is considered a senolytic peptide because it targets and removes senescent cells.